Rothenberg Mace
SEC insider (Form 3/4/5 filer). CIK 0001873988. Director at Tango Therapeutics, Inc. (TNGX) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 5, 2026. Located in BOSTON, MA.
Companies Rothenberg Mace has filed insider reports for
- Tango Therapeutics, Inc. (TNGX): Director
- Surrozen, Inc./DE (SRZN): Director
Rothenberg Mace
CIK: 0001873988
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 5, 2026TNGX
Tango Therapeutics, Inc.
AwardDirect4K shares- - May 13, 2026SRZN
Surrozen, Inc./DE
AwardDirectDirector Stock Option (right to buy)
5.6K shares- - Jun 5, 2025TNGX
Tango Therapeutics, Inc.
AwardDirect6.3K shares- - May 14, 2025SRZN
Surrozen, Inc./DE
AwardDirectOption (right to buy)
1.3K shares- - Nov 18, 2024TNGX
Tango Therapeutics, Inc.
PurchaseDirect10K shares at avg. $3.78$38K - Nov 14, 2024TNGX
Tango Therapeutics, Inc.
PurchaseDirect10K shares at avg. $3.62$36K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 5, 2026 |  TNGX Tango Therapeutics, Inc. | Award | 4,000 | - | $0 | Direct |
| May 13, 2026 |  SRZN Surrozen, Inc./DE | Award Director Stock Option (right to buy) | 5,550 | - | - | Direct |
| Jun 5, 2025 | TNGX Tango Therapeutics, Inc. | Award | 6,250 | - | - | Direct |
| May 14, 2025 | SRZN Surrozen, Inc./DE | Award Option (right to buy) | 1,333 | - | - | Direct |
| Nov 18, 2024 | TNGX Tango Therapeutics, Inc. | Purchase | 10,000 | $3.78 | $37,800 | Direct |
| Nov 14, 2024 | TNGX Tango Therapeutics, Inc. | Purchase | 10,000 | $3.62 | $36,200 | Direct |
1-6 of 6 transactions